BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 16420920)

  • 1. [Variation in the prognostic value of p53 protein in relation to tumoral stage in patients with colorectal adenocarcinoma].
    Díez M; Pollán M; Ramos P; Villeta R; Ratia T; Hernández P; Lozano O; Noguerales F; Granell J
    Cir Esp; 2005 Apr; 77(4):213-20. PubMed ID: 16420920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time-dependency of the prognostic effect of carcinoembryonic antigen and p53 protein in colorectal adenocarcinoma.
    Diez M; Pollan M; Müguerza JM; Gaspar MJ; Duce AM; Alvarez MJ; Ratia T; Herñandez P; Ruiz A; Granell J
    Cancer; 2000 Jan; 88(1):35-41. PubMed ID: 10618603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma.
    Giatromanolaki A; Stathopoulos GP; Tsiompanou E; Papadimitriou C; Georgoulias V; Gatter KC; Harris AL; Koukourakis MI
    Cancer; 1999 Oct; 86(8):1421-30. PubMed ID: 10526268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of tumor localization on the prognostic value of P53 protein in colorectal adenocarcinomas.
    Diez M; Medrano M; Mugüerza JM; Ramos P; Hernandez P; Villeta R; Martín A; Noguerales F; Ruiz A; Granell J
    Anticancer Res; 2000; 20(5C):3907-12. PubMed ID: 11268475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas.
    Bosari S; Viale G; Bossi P; Maggioni M; Coggi G; Murray JJ; Lee AK
    J Natl Cancer Inst; 1994 May; 86(9):681-7. PubMed ID: 8158699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival.
    Rosati G; Chiacchio R; Reggiardo G; De Sanctis D; Manzione L
    Tumour Biol; 2004; 25(5-6):258-63. PubMed ID: 15627889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of p53 expression and p21 loss has an independent prognostic impact on sporadic colorectal cancer.
    Noske A; Lipka S; Budczies J; Müller K; Loddenkemper C; Buhr HJ; Kruschewski M
    Oncol Rep; 2009 Jul; 22(1):3-9. PubMed ID: 19513497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
    Chang SC; Lin JK; Lin TC; Liang WY
    Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the immunohistochemical expressions of p53, bcl-2 and Ki-67 in colorectal adenocarcinoma and their correlations with the prognostic factors.
    Menezes HL; Jucá MJ; Gomes EG; Nunes BL; Costa HO; Matos D
    Arq Gastroenterol; 2010; 47(2):141-7. PubMed ID: 20721457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of p53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumors.
    Schelwies K; Sturm I; Grabowski P; Scherübl H; Schindler I; Hermann S; Stein H; Buhr HJ; Riecken EO; Zeitz M; Dörken B; Daniel PT
    Int J Cancer; 2002 Jun; 99(4):589-96. PubMed ID: 11992551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of thymidylate synthase and p53 protein expression on clinical outcome in patients with colorectal cancer.
    Broll R; Busch P; Duchrow M; Oevermann E; Schwandner O; Farke S; Bruch HP; Windhövel U
    Int J Colorectal Dis; 2005 Mar; 20(2):94-102. PubMed ID: 15309465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hierarchical investigating the predictive value of p53, COX2, EGFR, nm23 in the post-operative patients with colorectal carcinoma.
    Du P; Xu B; Zhang D; Shao Y; Zheng X; Li X; Xiong Y; Wu C; Jiang J
    Oncotarget; 2017 Jan; 8(1):954-966. PubMed ID: 27888614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the correlation between p53 and bcl-2 expression with staging and prognosis of the colorectal adenocarcinoma.
    Lustosa SA; Logullo A; Artigiani R; Saad SS; Goldenberg A; Matos D
    Acta Cir Bras; 2005; 20(5):353-7. PubMed ID: 16186958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of four antibodies in detecting p53 protein for predicting clinicopathological and prognostic significance in colorectal adenocarcinoma.
    Zhang Hong
    Clin Cancer Res; 1999 Dec; 5(12):4126-32. PubMed ID: 10632350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer.
    Wang L; Liu Z; Fisher KW; Ren F; Lv J; Davidson DD; Baldridge LA; Du X; Cheng L
    Hum Pathol; 2018 Jan; 71():20-29. PubMed ID: 28782638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection.
    Liang JT; Huang KC; Cheng YM; Hsu HC; Cheng AL; Hsu CH; Yeh KH; Wang SM; Chang KJ
    Int J Cancer; 2002 Feb; 97(4):451-7. PubMed ID: 11802206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy.
    Díez M; Medrano MJ; Gutierrez A; López A; Mugüerza JM; Hernández P; Lozano O; Noguerales F; Ruíz A; Granell J
    Anticancer Res; 2000; 20(5C):3929-33. PubMed ID: 11268479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
    Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM
    Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A comparative study on the prognostic value of the nuclear expression of protein p53 vis-à-vis histopathology in colorectal cancer].
    Díez M; Camuñas J; Enríquez JM; González A; Torabuela E; Gutiérrez A; Ratia T; Mugüerza JM; Martín A; Ruiz A; Granell J
    An Med Interna; 1996 May; 13(5):222-6. PubMed ID: 8767868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined metallothioneins and p53 proteins expression as a prognostic marker in patients with Dukes stage B and C colorectal cancer.
    Arriaga JM; Bravo IA; Bruno L; Morales Bayo S; Hannois A; Sanchez Loria F; Pairola F; Huertas E; Roberti MP; Rocca YS; Aris M; Barrio MM; Baffa Trasci S; Levy EM; Mordoh J; Bianchini M
    Hum Pathol; 2012 Oct; 43(10):1695-703. PubMed ID: 22516242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.